Newsroom

LONDON--(BUSINESS WIRE)--  PRE-STABILISATION ANNOUNCEMENT Date: 9th June 2026 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. Alstom SA Pre-stabilisation Period Announcement Natixis (contact: Christopher Agathangelou; telephone: 0158550814) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance wi...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...

HANOI, Vietnam--(BUSINESS WIRE)--Global technology corporation FPT and Amata Group, a leading industrial estate developer in Southeast Asia (SEA), have signed a Memorandum of Understanding (MOU) to advance AI-driven transformation across Amata’s industrial parks in Thailand, Vietnam, and the broader Southeast Asia region. The MoU exchange ceremony was witnessed by Thailand's Prime Minister, H.E. Anutin Charnvirakul. Under the agreement, FPT and Amata will explore a comprehensive set of collabor...

SYDNEY--(BUSINESS WIRE)--InterSystems, a creative data technology provider powering more than one billion healthcare records globally, today announced that Gateway Health, a leading not-for-profit regional community health service, has implemented a new InterSystems TrakCare® community solution for Australia. The solution – which Gateway Health co-designed over a six-month period as an InterSystems testing partner – has been configured to meet the needs of Australian community health services a...

LONDON--(BUSINESS WIRE)--  FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the...

LJUBLJANA, Slovenia--(BUSINESS WIRE)--Cosylab oggi ha annunciato il lancio di PlanOne™, un sistema di pianificazione del trattamento per l'adroterapia, che offre la pianificazione su base radiobiologica con la precisione della fisica e un flusso di lavoro clinico unificato in un unico ambiente. PlanOne™ ha ricevuto l'autorizzazione dell'FDA 510(k). "PlanOne™ ha avuto inizio con l'ascolto. Negli anni, il nostro lavoro sui sistemi di controllo in radioterapia ci ha messo a diretto contatto costan...

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) today announced that it has completed the core development of a direct ocean capture (DOC) system that removes CO2 via seawater, working in collaboration with VTT Technical Research Centre of Finland Ltd., headquartered in Espoo, Finland and headed by CEO Kalle Härkki. Supported by verified system performance and accumulated experimental data, Mitsubishi Electric and VTT are accelerating their efforts toward early deployment...

スロベニア・リュブリャナ--(BUSINESS WIRE)--（ビジネスワイヤ） -- Cosylabは、粒子線治療用の治療計画システムPlanOne™の商用開始を発表しました。本システムは、物理的に正確で放射線生物学的な知見に基づいた計画作成と、統一された臨床ワークフローとを単一の環境で実現します。PlanOne™は、FDA 510(k)取得済みです。 「PlanOne™の開発は、現場に耳を傾けることから始まりました。長年にわたる放射線腫瘍学の制御システムに関する取り組みを通じて、私たちは世界をリードする施設で働く医学物理士や臨床チームと直接かつ継続的に連携してきました」と、Cosylabの最高経営責任者（CEO）であるマーク・プレスコは述べています。「パートナーの皆様は、粒子線治療において何が最も重要であるかについて明確な考えを示してきました。それは、正当性を主張できる物理的な正確性、計画承認時における臨床的な信頼性、そしてAIや適応型ワークフローと共に成長できるプラットフォームです。PlanOne™の設計はこれら3つの優先事項を軸にしており、今後も製品形成に協力してくれた臨床コ...

LIUBLIANA, Eslovenia--(BUSINESS WIRE)--Cosylab anunció hoy el lanzamiento comercial de PlanOne™, un sistema de planificación de tratamientos para terapia de partículas que integra en un único entorno planificación con precisión física basada en información radiobiológica y un flujo de trabajo clínico unificado. PlanOne™ cuenta con la aprobación 510(k) de la FDA. "PlanOne™ comenzó escuchando. A lo largo de los años, nuestro trabajo en sistemas de control en oncología radioterápica nos ha puesto...

LJUBLJANA, Slovénie--(BUSINESS WIRE)--Cosylab a annoncé aujourd’hui le lancement commercial de PlanOne™, un système de planification de traitement pour la thérapie par particules qui réunit dans un environnement unique une planification précise sur le plan physique et radiobiologique, ainsi qu’un flux de travail clinique unifié. PlanOne™ a reçu l’autorisation 510(k) de la FDA. « Le développement de PlanOne™ est né d’une écoute attentive. Au fil des années, notre travail sur les systèmes de cont...